Morning Market Losers

Theravance Inc. THRX shares fell 7.57% to $16.61. GSK and Theravance announced the outcome of US FDA Advisory Committee on BREO(R) ELLIPTA(R) in asthma. Glaxo and Theravance announced that the FDA panel has voted to support efficacy and safety. The panel has voted against the approval for proposed indication in 12-17 olds. The Macerich Company MAC shares dipped 6.86% to $87.09 following announcement of Simon final offer. Simon Property Group Inc SPG raised its offer for Macerich to $95.50 per share in cash and stock. Cerulean Pharma Inc. CERU fell 3.65% to $10.27. Cerulean Pharma announced that a Phase 1b/2 trial of CRLX101 in combination with Avastin® in relapsed renal cell carcinoma met primary endpoint. Tiffany & Co. TIF shares dropped 1.26% to $85.28, despite the company reporting in-line earnings for the fourth quarter. The company's weak forecast exerted pressure on the shares. OXiGENE, Inc. OXGN shares declined 1.21% to $1.63 after the company announced at-the-market $10 million dollar offering at $1.7125 per share. Veracyte, Inc. VCYT slipped 1.20% to $8.20 after the company reported a wider-than-expected quarterly loss.